The real breakthrough to successful antibacterial chemotherapy was caused by the development of sulfonamides and penicillin. Subsequently numerous other antibiotics were developed and successfully applied. Whilst both the percentage share as well as the resistance pattern with different bacterial strains has remained more or less stable in Europe as well as in the US over the past ten years, staphylococci, especially Staphylococcus epidermidis, appear to increase consistently. This fact can above all be seen with blood cultures. Within the Viennese clinical material, the staphylococcal share increased between 1984 and 1989 from 40 to 48%, with material from intensive care units from 42 to 60% and at the burn care unit up to almost 90% with S. epidermidis counting for the largest share. The resistance pattern has hardly changed. The lethality of patients with staphylococcal sepsis only depended on the timing of treatment: even with targeted treatment starting within two days from onset of clinical symptoms we lost 29%, when therapy was started later, lethality increased to 50%, and without treatment to 90%. Only fast diagnosis can help to fully utilize the benefits offered by antibacterial chemotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01644736 | DOI Listing |
Curr Drug Saf
January 2025
National Center Chalbi Belkahia of Pharmacovigilance, Department of Collection and Analysis of Adverse Effects, Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, Tunis, Tunisia.
Background: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.
View Article and Find Full Text PDFPan Afr Med J
January 2025
Muhimbili National Hospital, Dar es Salaam, Tanzania.
Hyper immunoglobulin M (IgM) syndromes are a collection of uncommon primary combined immunodeficiency disorders. They are characterized by recurrent bacterial infections due to low levels of IgG, IgA, and IgE, while IgM levels remain normal or high. These conditions stem from a mutation in the CD40 ligand gene or disruptions in the CD40-signaling pathway.
View Article and Find Full Text PDFOtolaryngol Pol
January 2025
"P.U.M.A." Platform for Unique Models Application, Department of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, Wroclaw, Poland.
1,8-cineole, renowned for its versatile therapeutic properties, has long been utilized in the treatment of respiratory system disorders. Its potential for oral administration offers a new dimension as an effective systemic therapy with anti-inflammatory and antibacterial effects. Maintaining stable levels of the compound in the body enhances treatment efficacy and reduces the risk of recurrence.
View Article and Find Full Text PDFBMC Pharmacol Toxicol
January 2025
Medical Surgical Nursing, Department of Nursing, School of Nursing and Midwifery, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Background: The global dissemination of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp) poses a critical threat to public health. However, comprehensive data on the prevalence and resistance rates of CR-hvKp are limited. This systematic review and meta-analysis aim to estimate the pooled prevalence of carbapenem resistance among hvKp strains and assess the distribution of carbapenemase genes.
View Article and Find Full Text PDFAnn Clin Microbiol Antimicrob
January 2025
Laboratoire des Mycobactéries, Institut des Agents Infectieux, Laboratoire de Biologie Médicale Multi-Site, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
Background: Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is uncertain. Inducible resistance to macrolides (macrolides-iR) has been associated with poor clinical response in pulmonary infections, whilst for extra-pulmonary infections data are scarce.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!